Ann Pharmacol Pharm | Volume 2, Issue 1 | Review Article | Open Access
Fabio Pastorino, Chiara Brignole, Daniela Di Paolo, Patrizia Perri and Mirco Ponzoni*
Department of Oncology, Istituto Giannina Gaslini, Italy
*Correspondance to: Mirco Ponzoni
Fulltext PDFNeuroblastoma is a rare pediatric cancer characterized by a wide clinical behavior and adverse outcome despite aggressive therapies. New approaches with targeted therapies may improve efficacy and decrease toxicity. Nanotechnology offers potential developments in pharmaceutical, medical imaging and diagnosis and cancer treatment. We demonstrated that novel doxorubicin loaded nano carriers functionalized with neuroblastoma-selective peptides increases tumor vascular permeability and perfusion, enhances tumor penetration, leading to a delay of orthotopic tumor growth, and abrogates metastatic spreading through decreased tumor glucose consumption, accompanied by absence of systemic toxicity. Our findings are functional to the design of targeted nanocarriers with potentiated therapeutic efficacy towards the clinical translation and they open the way for developing.
Pastorino F, Brignole C, Di Paolo D, Perri P, Ponzoni M. How to Overcome Biologic Barriers for the Therapy of Neuroblastoma: The Tumor Vascular Targeted Approach. Ann Pharmacol Pharm. 2017; 2(1): 1010.